This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindenfeld, J. Search for Related Content PubMed PubMed Citation Articles by Lindenfeld, J.

Hormone replacement therapy is associated with improved survival in women with advanced heart failure

JoAnn Lindenfeld, MD^*,*, Jalal K. Ghali, MD, Heidi J. Krause-Steinrauf, MS, Steven Khan, MD, Kirkwood Adams, Jr, MD^||, Steven Goldman, MD^¶, Mary Ann Peberdy, MD^#, Clyde Yancy, MD^**, Surai Thaneemit-Chen, MS, Rhonda L. Larsen, RN, James Young, MD, Brian Lowes, MD^*, Yves D. Rosenberg, MD BEST Investigators

^* University of Colorado Health Sciences Center and Center for Women’s Health Research, Denver, Colorado, USA
Cardiac Centers of Louisiana, Shreveport, Louisiana, USA
National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
Cedars-Sinai Medical Center, Los Angeles, California, USA
^|| University of North Carolina, Chapel Hill, North Carolina, USA
^¶ Tucson SAVAHCS, Tucson, Arizona, USA
^# Virginia Commonwealth University, Medical College of Virginia, Richmond, Virginia, USA
^** University of Texas Southwestern, Dallas, Texas, USA
VA Palo Alto Health Care System Cooperative Studies Program, Palo Alto, California, USA
Duke Clinical Research Institute, Durham, North Carolina, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA

View larger version (11K): [in a new window]   Figure 1 Model-based survival curves for survival by hormone replacement therapy (HRT) use in postmenopausal women. Difference between HRT subgroups is significant. (Wald chi-square p value for HRT = 0.04) Adjustment was made for etiology of disease (coronary artery disease vs. non-coronary artery disease), cardiothoracic ratio, New York Heart Association functional classification, left ventricular ejection fraction, and treatment group. CI = confidence interval; HR = hazard ratio.

View larger version (17K): [in a new window]   Figure 2 Model-based survival curves by hormone replacement therapy (HRT) use within etiology of disease. Differences are significant for women with a non-coronary artery disease (CAD) etiology but not for those with a CAD etiology. Adjustment was made for cardiothoracic ratio, New York Heart Association functional classification, left ventricular ejection fraction, and treatment group. CI = confidence interval; HR = hazard ratio.